FY2024 EPS Estimates for QNRX Decreased by Zacks Small Cap

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) – Stock analysts at Zacks Small Cap cut their FY2024 earnings estimates for shares of Quoin Pharmaceuticals in a research note issued to investors on Tuesday, November 12th. Zacks Small Cap analyst M. Marin now anticipates that the company will post earnings of ($2.05) per share for the year, down from their previous estimate of ($2.02). The consensus estimate for Quoin Pharmaceuticals’ current full-year earnings is ($2.05) per share. Zacks Small Cap also issued estimates for Quoin Pharmaceuticals’ FY2025 earnings at ($2.00) EPS.

Quoin Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ:QNRX opened at $0.62 on Thursday. Quoin Pharmaceuticals has a fifty-two week low of $0.48 and a fifty-two week high of $6.18. The firm’s 50-day simple moving average is $0.64 and its 200-day simple moving average is $0.65. The company has a market cap of $3.13 million, a price-to-earnings ratio of -0.15 and a beta of 1.85.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.77% of Quoin Pharmaceuticals at the end of the most recent reporting period. 8.63% of the stock is owned by hedge funds and other institutional investors.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.